OXONIC ACID POTASSIUM SALT Chemical Properties

Melting point:

300 °C(lit.)

storage temp. 

Inert atmosphere,2-8°C

solubility 

Aqueous Base (Slightly), Water (Slightly, Heated, Sonicated)

form 

Powder

color 

White

biological source

rabbit

Water Solubility 

Soluble in hot water.

InChI

InChI=1S/C4H3N3O4.K/c8-2(9)1-5-3(10)7-4(11)6-1;/h(H,8,9)(H2,5,6,7,10,11);/q;+1/p-1

InChIKey

IAPCTXZQXAVYNG-UHFFFAOYSA-M

SMILES

C1(C([O-])=O)=NC(NC(=O)N1)=O.[K+]

CAS DataBase Reference

2207-75-2(CAS DataBase Reference)

Safety Information

Safety Statements 

24/25

WGK Germany 

3

RTECS 

RR4580000

HS Code 

29349990

MSDS

• Language:English Provider:4,6-Dihydroxy-1,3,5-triazine-2-carboxylic acid potassium salt
• Language:English Provider:ACROS
• Language:English Provider:SigmaAldrich

OXONIC ACID POTASSIUM SALT Usage And Synthesis

Description

Oxonic acid is a uricase inhibitor that prevents metabolism and excretion of uric acid and induces embryotoxicity and nephrotoxicity in rats. It is a component of S-1, a mixture containing a prodrug of the antitumor agent 5-fluorouracil (5-FU; ), that suppresses the gastrointestinal toxicity of 5-FU without inhibiting its antitumor activity in rats. Formulations containing oxonic acid have been used to treat gastric, pancreatic, lung, head, neck, and breast carcinomas.

Chemical Properties

Off-White Solid

Uses

Antitumor effect potentiator and antitumor agent

Uses

Oxonic acid potassium salt is an inhibitor of uricase. The product from Sigma has been used for the inhibition of 5-fluorouracil-induced gastrointestinal toxicity without the loss of its antitumor activity in rats. It has also been used to induce hyperuricemia in rats; as it inhibits uric acid metabolism.

Definition

ChEBI: Potassium 2,6-dihydroxytriazinecarboxylate is an organic molecular entity.

Synthesis

The general procedure for synthesizing potassium oxonate from glacial acetic acid and allantoin was as follows: 3.2 kg of potassium hydroxide was dissolved in 11.4 L of water, added to a 20 L reactor to dissolve, and then cooled to 0~5 °C. 46 g of potassium iodide was added, and 0.9 kg of allantoin was added in batches and stirred until completely dissolved, keeping the temperature at 0~5 °C. Subsequently, 1.8 kg of bromine was slowly added dropwise, and the dropwise time was controlled at 9 hours (the experiment was divided into the first 1-8 groups according to the difference of bromine dropwise time). After the dropwise addition was completed, stirring was continued at 0~5°C for 1 h. Then the temperature was increased to 20~25°C and the reaction was kept at this temperature for 20 h. The reaction was carried out by HPLC. After confirming that the allantoin content was less than 0.6% by HPLC, the reaction solution was cooled to 0~5°C. The pH was adjusted to 5 with acetic acid and the reaction solution was filtered. The filter cake was washed with 3 L of water at 0~5°C and then with 1 L of room temperature ethanol. Finally, potassium oxonate was allowed to precipitate from a white potassium oxide crystalline solid at room temperature.

in vivo

References

[1] Patent: CN106083750, 2016, A. Location in patent: Paragraph 0019; 0020; 0021

OXONIC ACID POTASSIUM SALT(2207-75-2)Related Product Information

• Potassium iodate
• Potassium lactate
• 1,2,3-Propanetricarboxylicacid,2-hydroxy-,potassiumsalt
• Potassium iodide
• Potassium Acetate
• RESMETHRIN
• 1,3,5-Triazine
• DIOXOPROMETHAZINE HCL
• Potassium sodium tartrate
• Potassium persulfate
• Potassium Citrate
• Potassium sorbate
• Hydrochlorothiazide
• Potassium clavulanate
• (S)-ropivacaine hydrochloride hydrate
• Potassium chloride
• Phosphorus oxybromide
• Oxolinic acid-D5